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Abstract 
Purpose: To formulate and evaluate an antispasmodic drug, mebeverine hydrochloride (Mbv-HCl), as a 
local anesthetic mucoadhesive buccal tablet.  
Methods: Mbv-HCl loaded tablets were formulated, using a direct compression technique, with varying 
polymer concentrations including carbopol 934P alone, carbopol 934P/hydroxypropyl methylcellulose 
(HPMC) mixture, or carbopol 934P/chitosan mixture. The tablets were evaluated for physicochemical 
characteristics, in-vitro drug release, bioadhesive strength, swelling, ex-vivo residence time, ex-vivo 
permeation, drug permeation through the buccal membrane of sheep, and stability.  
Results: The results indicate that formulation F4, which contains HPMC/carbopol 934P (3:1), showed 
the best in-vitro drug release profile. The release kinetics for all the formulations fitted well with Hixson-
Crowell kinetic model. Bioadhesive strength, surface pH, and swelling index of F4 were 41.52, 6.36, and 
231.2 %, respectively. Maximum residence time ex-vivo was exhibited by formulation F4, showing a 
maximum residence time of about 330 min with 80 % of Mbv-HCl permeated in 6 h ex-vivo. F4 was 
stable after storage for 60 days at 25 oC/60 % RH and 40 oC/75 % RH, with non-significant change (p < 
0.05) in drug content, bioadhesive strength and in vitro release. 
Conclusion: The optimized mucoadhesive buccal formulation is promising for delivery of Mbv-HCl, and 
displays high bioadhesion and adequate permeability through sheep buccal membrane to achieve a 
local anesthetic action.    
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Mebeverine hydrochloride (Mbv-HCl) is an 
antispasmodic agent reported to have a strong 
local anesthetic activity with insignificant side 
effects when compared to other local anesthetics 
[1]. It is a crystalline powder, white in color, with 
good solubility in ethanol and water [2].  
 
A non-specific relaxant effect on vascular, 
cardiac and other smooth muscle is shown by 
Mbv-HCl [3]. Previous literature revealed that the 
activity of Mbv-HCl as a spasmolytic is not due to 
one particular system. Mbv-HCl has a polyvalent 
spasmolytic action where about three different 
mechanisms are involved. Detailed study and 
explanation of these mechanisms have been 
previously described by Hameed et al [4]. 
 
In dental procedures, topical local anesthetic 
agents are applied in order to ensure a painless 
treatment without the distress associated with 
needle injections for gingival or periodontal 
therapies [5]. Formulations need to have easy 
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application, remain on the applied tissue, and 
have sufficient effectiveness and stable storage. 
Topical anesthetics are used in the medical field 
to reduce the pain of operative procedures, to 
relieve the pain of superficial mucosal lesions, 
such as ulcers, to mask the discomfort of 
injections, and to anesthetize skin prior to vein 
puncture for general anesthesia or sedation [6]. 
Local anesthetics for topical application can be 
mixed with a number of different formulations. 
Efficacy can be affected by the type of 
preparation, such as thru sprays, emulsions, film 
strips, patches, and creams [7]. 
 
Transmucosal drug delivery systems are 
designed with mucoadhesive polymers that have 
specific characteristics such as high viscosity, 
molecular weight, long chain length, and 
flexibility of chain length [8]. Hydrophilic polymers 
and gelling agents are the most common 
components of broad classes of mucoadhesive 
polymers [9]. Hydrophilic polymers containing a 
carboxylic group exhibit better mucoadhesive 
characters, such as cellulose derivatives [10].  
 
Hydrogels, the other class of polymeric 
biomaterial, exhibit the basic characteristics of a 
hydrogel by swelling as it absorbs water, which 
leads to adhesion with the epithelial mucus, i.e., 
chitosan and polyacrylates [11]. Formulation of 
Mbv-HCl into suitable topical mucoadhesive 
tablets for local application to superficial mucosal 
is used to control various painful oral conditions. 
This approach consists of using several 
mucoadhesive polymers, such as chitosan, 
carbopol 934, and HPMC to provide sufficient 
residence time for the tablets. 
 
Contemporary research is primarily addressing 
the problem of retention by the delivery system in 
the oro-mucosal space over longer durations. 
Moreover, Mbv-HCl must be released in a 
controlled fashion to achieve pharmacological 
responses. Accordingly, the aim of this work was 
to develop anesthetic bioadhesive tablets 
containing Mbv-HCl. Additionally, we studied ex-
vivo buccal permeation through the buccal 
membrane of sheep and in vitro. The objective of 
this research was to formulate and evaluate 
mucoadhesive oral formulations of Mbv-HCl, 
which is an antispasmodic agent for use as a 






Mebeverine hydrochloride was obtained from 
MOEHS Fine Chemicals, Cantabria, Spain. 
Hydroxypropyl methylcellulose (HPMC) and 
carbopol 934P were purchased from Aqualon, 
United Kingdom. Chitosan was obtained from 
Fluka, U.SA while Avicel and magnesium 
stearate were purchased from Sigma-Aldrich, 
USA. 
  
Formulation of mucoadhesive buccal tablets  
 
Mbv-HCl tablet formulations of varying 
compositions were manufactured with a direct 
compression method using compaction 
equipment (ERWEKA, GmbH, AR 402, 
Germany) [12], according to Table 1. 
 
Evaluation of mucoadhesive buccal Mbv-HCl 
tablets  
 
Weight variation  
 
Approximately, a batch of ten tablets from 
different formulations was weighed (Erweka EB 
100, Germany) and the mean weight was 




Tablets were taken randomly from each batch 
and tested for hardness. The tablet hardness 
tester (Erweka TBH 200, Germany) was helpful 
for determining the actual strength required to 
make a visible fracture on a tablet. A vernier 
caliper (pre-calibrated) was used to measure 
thickness and diameter.  
 
Table 1: Composition of Mbv-HCl mucoadhesive buccal tablets 
 
Ingredient (mg)  F1 F2 F3 F4 F5 F6 F7 
Mbv-HCL 100 100 100 100 100 100 100 
Carbopol 934P  100 75 50 25 75 50 25 
HPMC  0 25 50 75 0 0 0 
Chitosan  0 0 0 0 25 50 75 
Mannitol  30 30 30 30 30 30 30 
Avicel 65 65 65 65 65 65 65 
Mg Stearate  5 5 5 5 5 5 5 
Total weight  300 300 300 300 300 300 300 
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The tester plunger was rolled down at a speed of 
20 mm/min. Crushing strength (T) as a measure 
of tensile strength was calculated as in Eq 1. 
 
T = 2F/πdt ………. (1) 
 
where F is referred as crushing load, and t and d 





Approximately twenty tablets from different 
formulations were weighed and put onto the 
drum of an Erweka Friabilator, type PTF1 
(Pharmatest, Hainburg, Germany). After 100 
revolutions of the drum, the tablets were de-
dusted and weighed [13]. Friability was 
calculated as the difference in weight, expressed 




Approximately ten tablets from different 
formulations were measured with the help of a 
digital micrometer (Mitutoyo Co., Kawasaki, 
Japan), and mean thickness was calculated. 
 
Content uniformity  
 
Ten tablets were taken from each formulation. 
This step was followed by crushing and mixing. 
Two-hundred mg of Mbv-HCl from the mixture 
were extracted using 100 mL of 0.1 M 
hydrochloric acid and then heated for 10 min in a 
water-bath (GFL Corporation; Model 1031, 
Germany) and shaken frequently.  
 
Sufficient 0.1 M hydrochloric acid was used to 
produce 250 mL that was added and then filtered 
[13]. The final solution absorbance was 
measured at λmax 263 nm using an ultraviolet–
visible spectrophotometer (Perkin Elmer, 
Shelton, USA). 
 
Microenvironment (superficial) pH  
 
Irritation of the buccal mucosa may be produced 
by the acidic or alkaline surface pH of the buccal 
tablets, and therefore must be kept as close to 
neutral as possible. The tablet was taken with 5 
mL distilled water and allowed to swell for 2 h. 
The pH was recorded while maintaining contact 
with a combined glass electrode for 1 min. 
(Erweka pH1004, Germany).  
 
Bioadhesion studies  
 
In the present experiment, fresh sheep buccal 
mucosa was used as a model mucosal surface to 
test bioadhesion strength. The local Institutional 
Review Board (L.I.R.B) for pre and veterinary 
research approved the experiments as per EU 
Directive- 2010 / 63 / EU on the basis of 
protection of animals used for scientific purposes 
(DHEW publication NIH 80 – 23). The 
experiments also adhered to the Principles of 
Laboratory Animal Care (NIH publication # 85 - 
23, 1985 (revised)[16]. Fresh buccal mucosa was 
taken from sheep and transported in a tyrode 
solution, with a composition comprised of 
glucose, sodium bicarbonate (NaHCO3) approx. 
1.0 g / L and sodium chloride (NaCl), potassium 
chloride (KCl), calcium chloride dihydrate 
(CaCl2.2H2O), and monosodium phosphate 
(NaH2PO4) in 8, 0.2, 0.134, 0.05 g/L, respectively 
at 40 oC [14]. Adhesion was measured as in Eq 
2. 
 
Force of adhesion (N) = (Bioadhesive 
strength/100)9.81………. (2) 
 
Ex-vivo residence time 
 
The mean residence time ex-vivo was 
determined using a modified USP II dissolution 
apparatus. A phosphate buffer of pH 6.8 was 
selected as dissolution medium for the release 
studies at 37 oC. Sheep buccal mucosa was 
mounted onto the glass surface and was 
attached to the apparatus.  
 
One side of the three tablets of each patch were 
hydrated by 15 μL buffer at pH 6.8. The hydrated 
surface was attached to contact with buccal 
mucosa. The secured tablets were immersed in 
the buffer solution. The paddle of the apparatus 
was set at 25 rpm and adjusted at a distance of 5 
cm from the tablet [15]. Mucosal erosion or 
detachment time was determined. 
 
Swelling test  
 
Swelling studies were conducted on 
approximately six buccal tablets. The tablets 
were weighed (W1) and placed individually in 5 
mL of phosphate buffer of pH 6.8 in glass petri 
dishes. Further, each tablet was removed slowly 
from the petri dish by removing the excess water. 
The removal was performed at 1, 2, 4, 6, 8 and 
12 h using filter paper. Hydration (H) of the 
tablets was computed as the difference in tablet 
weight before and after swelling, expressed as a 
percentage.  
 
In-vitro dissolution test  
 
The USP paddle II method was adopted to 
perform in-vitro study. Phosphate buffer at pH 
6.8 of approximately 450 mL was used as 
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dissolution medium at 37 ± 0.5 °C, with paddle 
speed at 50 rpm (Erweka, DT 700 LH, Germany) 
[15]. At time intervals (1 to 12 h) 5 mL samples 
were withdrawn. Mbv-HCl content was measured 
by an ultraviolet–visible spectrophotometer 




Kinetic studies are useful for understanding and 
determining the exact drug release rate and 
mechanism for various formulations. The 
following equations and models were applied for 
prediction: 
 
Zero-order kinetic model: 
 
If the drug does not disaggregate in the 
dissolution, then those results in slow drug 
release can be equated by 
 
Qt = Q0 + K0t………. (3) 
 
Qt is drug concentration dissolved in time t, Q0 is 
initial drug concentration in the solution (most 
times, Q0 = 0) and K0 is the constant (zero order 
release) (concentration / time). 
 
First-order kinetic model: 
 
log C = log C0 - Kt/2.303………. (4) 
 
where, C0 is initial drug concentration, k is 




ft = Q = KH.t1/2 ………. (5) 
 
where, KH is Higuchi dissolution constant, Q is 
drug concentration per time t and per unit area A. 
 
Korsmeyer-Peppas model:  
 
Mt/M∞ = Ktn ………. (6) 
 
where, k is release rate constant; Mt/M∞ is 
fraction of drug concentration released at time t; 
n is release exponent. When n equals 0.5, it is 
indicated as a Fickian or diffusion-controlled 
release and if 0.5 < n < 1.0 then it is indicated as 
non-Fickian transport. If n = 1, then it is zero 




Mo1/3 – M1/3 = kt …………….. (7) 
 
where Mo and M are the initial weight and weight 
of drug dissolved at time, t, respectively. 
Ex-vivo permeation studies 
 
Tissue isolation  
 
From freshly slaughtered sheep, buccal tissue 
was obtained and stored in Krebs buffer pH 6.8 
at a temperature of 4 °C. This study was 
approved by the Animal Ethics Committee, 
Faculty of Pharmacy, King Abdulaziz University 
(approval no. 423). The protocol complied with 
the guidelines of Declaration of Helsinki as well 
as the Principles in Care and Use of Animals 
(DHEW publication no .NIH 80-23) and 
‘‘Principles of Laboratory Animal Care’’ (NIH 
publication #85-23, revised in 1985). [16,17]The 
epithelium of mucosa was carefully isolated 
using a dissection procedure such that the basal 
marginal membrane was still intact and viable 
[16].  
 
Membrane permeability  
 
In a Franz diffusion cell, the sheep buccal 
membrane was mounted between the donor and 
acceptor compartment. The two chambers were 
tied to fix the buccal membrane. Phosphate 
buffer at pH 6.8 was used as the medium inside 
the acceptor compartment with turbulence at 400 
rpm. The optimized tablet (F4) was held inside 
the donor compartment. Sampling was done 
from the receptor compartment and an equal 
amount of medium was replaced in order to 
maintain sink conditions. Mbv-HCl concentration 
in the withdrawn aliquots was calculated by the 
equation, 
 
J = dQ/A dt ………. (8) 
 
where dQ / dt is the slope; J is the flux (mg h-1 
cm-2) and A is the diffusion area (cm2). 
 
Stability studies  
 
Based on previous evaluation tests, we selected 
formulation (F4), which was subjected to 
accelerated stability studies at 25 °C/60 % RH 
and 40 °C/75 % RH for 60 days in thermostatic 
ovens. At 0, 15, 30, 45, and 60 days, the tablets 
were tested for bioadhesive strength, content 
uniformity and drug release. 
 
Statistical analysis   
 
All the results in the present work are 
represented as mean ± standard deviation (SD, n 
= 3). One-way ANOVA was used to calculate the 
difference in statistical significance at a 
probability level of 0.05 using Minitab 17. 
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Mbv-HCl mucoadhesive buccal properties of 
tablets  
 
Table 2 presents the physical parameters of 
each corresponding tablet. Hardness, thickness 
and surface pH were within the limits of 
uniformity. Variation in weight for batches F1 to 
F7 formulations was between 295.5 ± 0.8 and 
304.4 ± 0.5 mg. Tablet friability ranged from 
0.113 ± 0.03 to 0.417 ± 0.06 % and drug content 
from 97.16 ± 0.15 to 103.21 ± 0.42 %. The 
surface pH of the formulations is indicated in 
Table 2, and is in agreement with normal salivary 
of pH 5.5 to 7.8. 
 
In-vitro drug release  
 
Figure 1 indicates that release was different 
based on the polymer type and its ratio. The 
release order was determined as F4 > F3 > F7 > 
F6, as shown in Figure 1. 
 
Drug release kinetics 
 
Drug release kinetics are shown in Table 3. The 
results showed that the drug released from 
formulations F2, F3, F4, F6, and F7 follow the 
Hixson-Crowell model (have higher R2), whereas 




Both type and concentration of the bioadhesive 
polymers affect bioadhesion characteristics. The 
strength of bioadhesion for F1 to F7 was found to 
be within the range of 20.21 ± 0.82 g to 41.52 ± 
0.64 g. Formulation F4 and F7 indicated 
maximum and minimum bioadhesive forces of 
about 4.073 ± 0.06 and 1.982 ± 0.09, 
respectively. All the formulation results are 
shown in Table 4. 
 








Weight (mg) Friability 
(%) 
Surface pH Drug content 
(%) 
F1 5.5±0.02 3.08±0.01 295.5±0.8 0.33±0.05 6.91±0.06 97.1±0.15 
F2 5.3±0.08 3.15±0.02 302.4±0.4 0.41±0.06 6.73±0.03 102.5±0.34 
F3 5.6±0.03 3.02±0.04 298.2±0.3 0.28±0.05 6.50±0.04 97.8±0.68 
F4 5.7±0.08 2.98±0.02 304.4±0.5 0.24±0.03 6.36±0.03 103.2±0.42 
F5 5.9±0.04 2.94±0.03 301.3±0.2 0.11±0.03 6.71±0.02 101.3±0.17 
F6 5.6±0.02 3.03±0.01 299.7±0.4 0.29±0.07 6.48±0.05 98.2±0.27 




Figure 1: In-vitro cumulative drug release profile of Mbv-HCl from different formulations F1 ( , 
Carbopol 934P alone); F2 ( , Carbopol 934P: HPMC 75:25); F3 ( , Carbopol 934P: HPMC 
50:50); F4 ( , Carbopol 934P: HPMC 25:75); F5 ( X Carbopol 934P: chitosan 75:25); F6 ( , 
Carbopol 934P: chitosan 50:50); F7 ( , Carbopol 934P: chitosan 25:75) 
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 R2 R2 R2 R2 R2 
F1 0.987 0.813 0.986 0.977 0.834 
F2 0.980 0.809 0.981 0.972 0.812 
F3 0.891 0.967 0.994 0.980 0.871 
F4 0.899 0.971 0.995 0.988 0.882 
F5 0.986 0.914 0.980 0.971 0.789 
F6 0.979 0.877 0.992 0.982 0.791 
F7 0.974 0.892 0.989 0.984 0.799 
 
Table 4: In-vitro bioadhesive strength and 









F1 31.2±0.64 3.06±0.05 
F2 34.1±0.19 3.35±0.08 
F3 40.3±0.45 3.95±0.07 
F4 41.5±0.64 4.07±0.06 
F5 27.2±0.42 2.67±0.04 
F6 23.9±0.61 2.34±0.06 
F7 20.2±0.82 1.98±0.09 
 
Swelling and ex-vivo residence time  
 
Formulations F1 to F7 have an ex-vivo residence 
time in the range of 200 ± 15 min to 345 ± 10 
min. The same formulas also have a swelling 
percent after 12 h. The results are illustrated in 
Table 5. The highest swelling (231.2 ± 11.2 %) 
was observed with formulation F4, and as as 





Formula 4 was stored at 25 ˚C/60 % RH and 40 
˚C/75 % RH for two months and was stable in 
different storage conditions, which is an 
important parameter for tablet evaluation (Table 
6). 
 
Ex-vivo permeation  
 
F4 was the most promising formulation and was 
used to study the ex-vivo permeation profile of 
the drug through inexpensive buccal tissues 
because it has good moisture absorption and 
bioadhesive strength. The results show that > 80 
% of Mbv-HCl permeated across the tissue in 6 
h. 
 
Table 5: Ex-vivo residence time and swelling 









F1 290±10 151.4±7.1 
F2 310±15 192.2±8.9 
F3 345±10 214.5±9.7 
F4 330±10 231.2±11.2 
F5 270±15 163.2±9.2 
F6 230±10 178.4±5.9 




Formulated mucoadhesive buccal tablets are 
promising in terms of adhering inside the oral 
space and sustaining the release of Mbv-HCl 
over long periods. HPMC, and carbopol 934P are 
hydrophilic polymers, inert in nature and exhibit a 
high capacity to entrap a drug [18]. The high 
swellability of these polymers aids in their use for 
modified release systems [19]. Chitosan is a 
cationic charged biopolymer commonly used in 
formulations of controlled and sustained 
therapeutic delivery systems [20]. The 
incorporation of a therapeutic moiety into the 
polymer matrix forms a single lithic device.
 
Table 6: Stability of formulation F4 after storage for two months at 25 ˚C/60 % RH and 40 ˚C/75 % RH 
 
Parameter Pre-storage  Post-storage (60 days at 
25˚C/60% RH) 
Post-storage (60 
days at 40˚C/75% 
RH) 
Drug Content (%) 103.2±0.42 102.6±0.31 100.1±0.62 
Bioadhesive-strength (g) 41.5±0.64 43.1±0.81 40.0±0.52 
In vitro drug release (%) 91.2±3.21 89.8±2.92 87.9±3.07 
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Figure 2: Ex-vivo permeation profile of Mbv-HCl ( F4) across sheep buccal tissue 
 
Purely on the basis of polymer concentration, film 
thickness around the tablet and the dissolution 
medium, the chemical entity release from the 
polymer filmed tablet can vary from hours to 
months [21]. 
 
Increasing the amount of hydrophilic polymer led 
to an increase in drug release rate. This is 
primarily because the polymers have the ability 
to absorb water, which enhanced dissolution and 
drug release. Additionally, the hydrophilic 
polymer creates a more porous structure and 
channel formation. The current study illustrates 
that the polymers, carbopol 934P, HPMC, and 
chitosan, which are hydrophilic polymers, in 
different ratios, result in different rates of drug 
release and different mucoadhesive force. For 
formulae F3 - F7, the drug release mechanism is 
erosion with a Hixson-Crowell model that 
describes the drug release mechanism from 
delivery systems with diameter as well as surface 
area changes in a respective tablet [22]. The 
kinetic data of formula F1 containing carbopol 
934P only, and from F5, which contained the 
lowest concentration of secondary polymer 
(chitosan), fit perfectly with a zero-order model. 
This indicates that release was independent of 
drug concentration.  
 
Increases in mucoadhesive strength by 
increasing the chitosan component was due to 
the interaction between the negative charge in 
the epithelium and the positive charge in 
chitosan. Changes in concentration and the type 
of bioadhesive polymer affect bioadhesive 
characteristics [23]. 
 
The swelling index was found to be the same for 
all the formulations F1 to F7. These results could 
be due to the presence of hydrophilic polymers in 
the formulation that will swell when coming into 
contact with water and enable a chain interaction 
within the mucin present in the buccal mucosa 
[24]. 
 
F4 formulation exhibited maximum permeation in 
comparison to other formulations. This could be 
attributed to the presence of a mucoadhesive 
polymer that ensures close contact between the 
drug and membrane. Additionally, the higher 
swelling index of this formula allows for the 
creation of pores and channels at the tablet 
surface, thus allowing ready diffusion of the drug 




Mebeverine hydrochloride, a well-known 
antispasmodic drug, has been successfully 
formulated as a local anesthetic mucoadhesive 
buccal tablet. The optimum tablet formulation 
contains carbopol 934 and HPMC in a ratio of 
1:3, and exhibits an ex-vivo residence time of 
330 min in sheep buccal tissue. The formulation 
is stable after 6 months of storage. Further 
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